Grant opportunity
The Role of the Innate Immune System in the Pathogenesis of Type 1 Diabetes
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
- Funder
- National Institutes of Health
- Forecast notice: deadline to be announced
- Forecast notice: deadline to be announced
- Award
- USD 15,000,000
- Applicant
- Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Special district governments; County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; City or township governments; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); State governments; For profit organizations other than small businesses
- Discipline
- Health and Biomedical Sciences
- Region
- United States
- Posted
- Sep 28, 2026
Call summary
Overview
The Role of the Innate Immune System in the Pathogenesis of Type 1 Diabetes is official opportunity RFA-AI-28-029, published by National Institutes of Health during the 18-22 August 2026 hunt window.
Who can apply
Eligible applicant types listed by the agency: Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Special district governments; County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; City or township governments; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); State governments; For profit organizations other than small businesses. Applicants must also satisfy every programme-specific condition in the official notice.
What it supports
- The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
- Opportunity number: RFA-AI-28-029
Funding and duration
- Estimated programme funding: USD 15,000,000
- Expected number of awards: 7
Forecast notice: deadline to be announced
Forecast notice: deadline to be announced
How to apply
Open the official Grants.gov record, review the full notice and attachments, and use the application package or agency route stated there.
Call details
Source-based overview
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200. The official record contains the controlling eligibility, budget, attachment and submission requirements for opportunity RFA-AI-28-029.
Eligibility
Eligible applicant types listed by the agency: Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Special district governments; County governments; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Public housing authorities/Indian housing authorities; City or township governments; Small businesses; Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); State governments; For profit organizations other than small businesses. Applicants must also satisfy every programme-specific condition in the official notice.
Funding and benefits
Estimated programme funding: USD 15,000,000
Expected number of awards: 7
Themes and supported activities
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to advance the National Institutes of Health (NIH) mission by utilizing Special Statutory Funding Program for Type 1 Diabetes Research funds to support studies focused on the involvement of the innate immune system in the initiation of Type 1 diabetes (T1D). This initiative directly aligns with the first goal of the congressionally mandated Special Diabetes Program, which is to identify the genetic and environmental causes of T1D. By engaging multidisciplinary teams with expertise in innate immunity and beta-cell biology, the program aims to elucidate how innate immune components interact with pancreatic tissues and beta cells. The program will leverage the use of new approach methodologies (NAMs) to precisely define the timing and impact of environmental perturbations that activate innate immune pathways. Ultimately, these studies may enable earlier identification of individuals at elevated risk for T1D (beyond genetic susceptibility) and lay the groundwork for future prevention and therapeutic strategies. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Opportunity number: RFA-AI-28-029
Deadline and timeline
Forecast notice: deadline to be announced: Forecast notice: deadline to be announced.
Applicants should confirm the exact deadline time, time zone, required documents, portal steps and any institutional approvals on the official call page before submitting.
How to apply
Open the official Grants.gov record, review the full notice and attachments, and use the application package or agency route stated there.
Before applying, check eligibility rules, budgets, attachments, page limits, partner requirements, cost-share conditions and whether the opportunity uses an expression of interest, full proposal, registration or nomination stage.